



# Current Lung-MAP Schema



<sup>1</sup> Acquired Resistance is defined as progression at least ( $\geq$ ) 84 days from initiation of the most recent line of anti-PD-1/PD-L1 and best response of stable disease, partial response, or complete response.

<sup>2</sup> Approved by the Lung-MAP Drug Selection Committee

**TRIAL POINTS OF INTEREST:**

- Each of sub-study operates independently of the others
- Prescreening can be performed while the patient is on any line of therapy for stage IV disease
- Repeat or fresh biopsy necessary for tissue screening is paid by the trial
- #Biomarker-driven sub-studies may progress to Phase III if study meets endpoint and Phase III is feasible, at which point the standard of care arm will be determined.